Organigram Global and Sanity Group jointly announced the official closing of Organigram’s acquisition of the Germany-based cannabis company that was originally announced in February. Combining cash and shares as part of its international expansion strategy, the deal is valued at €107.3 million. The transaction was supported by €40.3 million in new financing from British American Tobacco and additional credit facilities, highlighting BAT’s continued backing of Organigram’s growth initiatives. The deal marks the final deployment of funds from the Jupiter strategic investment pool and strengthens Organigram’s position in the European cannabis market.
Tag: Organigram
-
Organigram Shares Results of AGM, Gains Approval for Sanity Acquisition
Shareholders of Organigram Global Inc. overwhelmingly approved the company’s proposed acquisition of Germany-based Sanity Group GmbH and a related private placement with British American Tobacco subsidiary BT DE Investments at a meeting held on March 30. The transaction resolution passed with 93% of votes cast, excluding shares associated with BAT, and authorizes Organigram to issue up to 96.3 million common shares to Sanity Group shareholders and BAT in connection with the deal.
The acquisition, expected to close in April subject to customary conditions, is positioned to expand Organigram’s presence from its leading position in Canada’s adult-use market into the German medical cannabis sector and establish a broader European operational footprint. Shareholders also approved the election of 10 directors, the reappointment of PricewaterhouseCoopers LLP as auditor, and the approval of unallocated awards under the company’s long-term equity incentive plan.
-
BAT Funds $48M for Organigram’s Sanity Group Acquisition
Organigram Global Inc. revealed that it has entered into a subscription agreement with BT DE Investments Inc. – a wholly-owned subsidiary of British American Tobacco – to fund its previously announced acquisition of Sanity Group GmbH. Under the agreement, BAT will subscribe for 14,027,074 common shares at C$3 ($2.19) each and exercise top-up rights for 9,897,356 additional shares at C$2.335854 ($1.71), generating total gross proceeds of C$65.2 million ($47.6 million).
The proceeds, along with cash on hand and funds from a previously arranged up to $60 million senior secured credit facility, will be used to finance the cash portion of the acquisition, transaction costs, and general working capital. To ensure BAT does not exceed a 30% ownership threshold post-issuance, the company will issue non-voting Class A convertible preferred shares if needed, which can be converted into common shares under specified conditions. Shareholder approval for the acquisition and private placement will be sought at Organigram’s annual and special meeting on March 30, in compliance with TSX rules and related-party transaction regulations. The Board unanimously approved the deals, with BAT’s nominees abstaining from voting.
-
Organigram Closes Second BAT Tranche
Photo: krishnadasekm Organigram Holdings closed the second of three tranches of a CAD124.56 million ($92.2 million) equity investment by British American Tobacco’s BT DE Investments subsidiary.
Pursuant to the second tranche closing, the investor acquired 4,429,740 common shares and 8,463,435 Class A preferred shares at a price of CAD3.22 per share for gross proceeds of $30.82 million. The remaining 12,893,175 shares subscribed for are due to be issued at the per share price in the final tranche on or around Feb. 28, 2025.
“With two tranches of the Jupiter pool now funded, combined with our strong balance sheet and targeted investment strategy, Organigram is well on its way to executing on its ambitious growth plan focusing on international, technological and product expansion,” said Organigram CEP Paolo De Luca in a statement.
“Our inaugural Jupiter investment in Open Book Extracts marked our second investment in the U.S. market, and our first international investment in Sanity Group represents a significant first step in our ambitions to grow our footprint in the fast-growing German market,” he added.
-
Organigram Looking for New CFO
Image: fizkes Derrick West will transition away from his role as chief financial officer at Organigram Holdings to focus on recovery following surgery later this month.
Paolo De Luca, current chief strategy officer, has been appointed interim CFO while the company completes a search for a new permanent CFO. De Luca previously served as the company’s CFO between 2017 and 2020.
“Derrick has left a legacy of stabilizing our financial processes along with the implementation of our ERP and has supported the company through a period of high growth including the acquisitions of our Winnipeg and Lac-Supérieur facilities,” said Organigram CEO Beena Goldenberg in a statement. “We are grateful for his contributions during his time on the board beginning in 2017 and since becoming CFO in 2020 and we wish him well.”
Organigram Holdings is the parent company of Organigram, a licensed producer of cannabis, cannabis-derived products and cannabis infused edibles in Canada.
Recently British American Tobacco increased its equity position in Organigram from 19 percent to 45 percent.
-
BAT Ups Investment in Organigram
Credit: Roxxy Photos Organigram Holdings Inc. has extended its relationship with British American Tobacco. The move boosts the Canadian cannabis producer’s financial strength and positioning it to expand globally.
Organigram said in a statement that BAT is investing a further $90.5 million in the business, building on an initial $160 million injection back in 2021.
Organigram said the investment will allow it to extend its footprint beyond Canada, and also strengthen its financial position for long-term, sustainable growth, according to media reports.
“This investment bolsters an already strong balance sheet and solidifies our position as a leading cannabis company,” said Beena Goldenberg, chief executive of Organigram.
The firm said the deal enables it to invest in growing the topline of its core business, while optimizing operations to deliver on cost-saving efficiencies, thus accelerating earnings growth.
Organigram will use the majority of the investment to create a strategic investment pool, named Jupiter.
Jupiter will target investments in emerging cannabis opportunities that will enable Organigram to apply its industry-leading capabilities to new markets, it said.
-
BAT Strengthens Organigram Partnership
Image: weerapat1003 BAT is investing some £74 million ($91.68 million) in its partnership with Organigram and increasing its equity position from 19 percent to 45 percent.
This investment is intended to deepen the strategic relationship between Organigram Holdings and BAT, which has strengthened since BAT’s initial investment and the establishment of the Product Development Collaboration (PDC) in March 2021. The PDC was set up to leverage the expertise of both companies in order to develop the next generation of noncombustible cannabis products.
In a statement, BAT said it has been pleased with Organigram’s performance and continues to be impressed by the careful financial governance of the company. “BAT also remains supportive of the category stewardship displayed by Organigram’s management team, particularly in response to tough market conditions,” BAT wrote. “These factors give BAT confidence that the new investment can position Organigram to capitalize on market opportunities and deliver incremental value for both companies.”
The majority of the investment will be allocated for Organigram to establish a strategic investment pool, intended to be applied for emerging opportunities within the cannabis space to accelerate Organigram’s growth and to support geographic, technological and product expansion. According to BAT, the investment remains subject to customary conditions, including necessary approvals by the shareholders of Organigram.
“This investment bolsters an already strong balance sheet and solidifies our position as a leading cannabis company. In addition, this deepens the strategic partnership between Organigram and BAT, and we look forward to continuing to leverage BAT’s global capabilities and scientific expertise,” said Organigram CEO Beena Goldenberg in a statement.